Hemostemix advises the conclusion of the non-brokered convertibl

Hemostemix refreshed another release concerning the end of a non-brokered convertible debenture. The chief sum is convertible at the choice of the debenture holder into a common share of the company at the cost of $0.175 per normal offering.